TW200831491A - N-aryl pyrazole compounds, compositions, and methods for their use - Google Patents

N-aryl pyrazole compounds, compositions, and methods for their use Download PDF

Info

Publication number
TW200831491A
TW200831491A TW096137866A TW96137866A TW200831491A TW 200831491 A TW200831491 A TW 200831491A TW 096137866 A TW096137866 A TW 096137866A TW 96137866 A TW96137866 A TW 96137866A TW 200831491 A TW200831491 A TW 200831491A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
methyl
compound
aryl
Prior art date
Application number
TW096137866A
Other languages
English (en)
Chinese (zh)
Inventor
Yasuyuki Ogawa
Ryo Okuyama
Satoshi Shibuya
Narihiro Toda
Zhaodan Cao
Zice Fu
Xiaolin Hao
Yong-Jae Kim
Leping Li
Sarah E Lively
Mike Lizarzaburu
Hui Tian
Ming Yu
Original Assignee
Amgen Inc
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Daiichi Sankyo Co Ltd filed Critical Amgen Inc
Publication of TW200831491A publication Critical patent/TW200831491A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096137866A 2006-10-10 2007-10-09 N-aryl pyrazole compounds, compositions, and methods for their use TW200831491A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85108306P 2006-10-10 2006-10-10

Publications (1)

Publication Number Publication Date
TW200831491A true TW200831491A (en) 2008-08-01

Family

ID=39047570

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096137866A TW200831491A (en) 2006-10-10 2007-10-09 N-aryl pyrazole compounds, compositions, and methods for their use

Country Status (12)

Country Link
US (1) US8022061B2 (enExample)
EP (1) EP2079728B1 (enExample)
JP (1) JP2010505957A (enExample)
AR (1) AR063240A1 (enExample)
AU (1) AU2007308154A1 (enExample)
CA (1) CA2675511A1 (enExample)
CL (1) CL2007002904A1 (enExample)
ES (1) ES2430821T3 (enExample)
MX (1) MX2009003821A (enExample)
PE (1) PE20080858A1 (enExample)
TW (1) TW200831491A (enExample)
WO (1) WO2008045484A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101152162B1 (ko) 2006-12-08 2012-07-10 에프. 호프만-라 로슈 아게 치환된 피리미딘 및 jnk 조절제로서 그의 용도
SG187396A1 (en) * 2007-07-19 2013-02-28 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2698332C (en) 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
WO2010099054A2 (en) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2571359A4 (en) * 2010-05-20 2013-10-23 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201504410PA (en) 2012-12-07 2015-07-30 Chemocentryx Inc Diazole lactams
WO2014100735A2 (en) * 2012-12-21 2014-06-26 Chemocentryx, Inc. Diazole amides
CN103772282B (zh) * 2014-02-26 2015-09-23 上海毕得医药科技有限公司 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
KR102808827B1 (ko) * 2016-02-05 2025-05-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
AU2017246460B2 (en) 2016-04-07 2021-04-22 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
EP3552017B1 (en) 2016-12-09 2022-02-23 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
CN111902408B (zh) * 2018-04-04 2023-11-14 日本烟草产业株式会社 杂芳基取代的吡唑化合物及其药物用途
EP3817811B1 (en) 2018-07-04 2024-04-03 Boehringer Ingelheim International GmbH Triazole benzamide derivatives as gpr142 agonists
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2025503642A (ja) 2022-01-12 2025-02-04 デナリ セラピューティクス インコーポレイテッド (s)-5-ベンジル-n-(5-メチル-4-オキソ-2,3,4,5-テトラヒドロピリド[3,2-b][1,4]オキサゼピン-3-イル)-4h-1,2,4-トリアゾール-3-カルボキサミドの結晶性形態

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778433A (en) 1969-04-18 1973-12-11 Sumitomo Chemical Co Process for producing benzodiazepine derivatives
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH04145081A (ja) 1990-10-06 1992-05-19 Kumiai Chem Ind Co Ltd ピラゾールカルボン酸誘導体及び除草剤
TW312694B (enExample) 1994-09-26 1997-08-11 Daiichi Seiyaku Co
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998024782A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
US6169086B1 (en) 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
AU725548B2 (en) 1997-03-11 2000-10-12 E.I. Du Pont De Nemours And Company Heteroaryl azole herbicides
BR0111158A (pt) 2000-05-12 2004-04-06 Genzyme Corp Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
WO2002023986A1 (en) 2000-08-25 2002-03-28 Sankyo Company, Limited 4-acylaminopyrazole derivatives
US20040198758A1 (en) 2001-08-17 2004-10-07 Rapado Liliana Parra N-heterocyclyl substituted thienyloxy-pyrimidines used as herbicides
DE60235114D1 (de) 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
DE10234876A1 (de) 2002-07-25 2004-02-05 Bayer Cropscience Gmbh 4-Trifluormethylpyrazolyl substituierte Pyridine und Pyrimidine
JP3774184B2 (ja) 2002-10-25 2006-05-10 株式会社フジクラ 光ファイバ心線テープ被覆除去具及び光ファイバ心線テープ被覆除去方法
DE602004029242D1 (en) 2003-05-01 2010-11-04 Bristol Myers Squibb Co Pyrazolamidverbindungen
JP2004339080A (ja) 2003-05-13 2004-12-02 Tokyo Institute Of Technology ピラゾ−ル誘導体を含有する高血圧治療剤
US6818631B1 (en) 2003-08-15 2004-11-16 Nippon Soda Co. Ltd. Fungicidal pyrimidine derivatives
BRPI0417478A (pt) 2003-12-15 2007-05-08 Almirall Prodesfarma Ag 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US20090275586A1 (en) * 2006-10-06 2009-11-05 Kalypsys, Inc. Heterocyclic inhibitors of pde4

Also Published As

Publication number Publication date
EP2079728B1 (en) 2013-09-25
CL2007002904A1 (es) 2008-06-06
EP2079728A1 (en) 2009-07-22
US20080153778A1 (en) 2008-06-26
CA2675511A1 (en) 2008-04-17
JP2010505957A (ja) 2010-02-25
PE20080858A1 (es) 2008-08-06
MX2009003821A (es) 2009-05-25
ES2430821T3 (es) 2013-11-21
AU2007308154A1 (en) 2008-04-17
US8022061B2 (en) 2011-09-20
AR063240A1 (es) 2009-01-14
WO2008045484A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
TW200831491A (en) N-aryl pyrazole compounds, compositions, and methods for their use
US12264169B2 (en) Heteroaryl inhibitors of PDE4
ES2303565T3 (es) Derivados de aminobenzamida como inhibidores de la glucogeno sintasa cinasa 3beta.
TWI445707B (zh) 葡萄糖激酶活化劑
EP3510025B1 (en) Heteroaryl inhibitors of pad4
WO2009117421A2 (en) Heterocyclic modulators of gpr119 for treatment of disease
EP3101015B1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
JP6077468B2 (ja) 不斉尿素及びその医学的用途
MX2014013751A (es) Piridazina y derivados de piridina como inhibidores de nampt.
WO2010048149A2 (en) Heterocyclic modulators of gpr119 for treatment of disease
TW200838517A (en) Compounds useful as protein kinases inhibitors
CN101686967A (zh) 作为nadph氧化酶抑制剂的吡唑并吡啶衍生物
TW200900064A (en) Pyrrole compounds
DK2928474T3 (en) Diazollactamer
TW200808805A (en) Tetrahydropteridines useful as inhibitors of protein kinases
MX2014013734A (es) Inhibidores de nampt.
US20200262850A1 (en) Substituted asymmetric ureas as modulators of ghrelin receptor activity
TW201217335A (en) Prostaglandin d synthase inhibitory piperidine compounds
CA3195859A1 (en) Inhaled formulations of pgdh inhibitors and methods of use thereof
TW202146384A (zh) 取代的氮雜五元環類化合物及其在藥物中的應用
CN107207477A (zh) 用于治疗病毒性疾病的亚氨基糖